Guggenheim analyst Paul Jeng initiates coverage on Corbus Pharmaceuticals (NASDAQ: CRBP) with a Buy rating and a price target of $45.00.

For an analyst ratings summary and ratings history on Corbus Pharmaceuticals click here. For more ratings news on Corbus Pharmaceuticals click here.

Shares of Corbus Pharmaceuticals closed at $10.08 yesterday.